4547:TYO
Kissei Pharmaceutical Co Ltd
Â¥4,095.00
0.00%
(0.00) 1D
Jul 3, 3:30:00 PM GMT+9 · JPY
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 4547...
Open
Â¥4,165
High
Â¥4,190
Low
Â¥4,095
Mkt. cap
190.59B
Avg. vol.
130.81K
Volume
100.80K
Dividend
2.93%
Quarterly dividend
Â¥30
Ex-dividend date
Mar 30, 2026
P/E ratio
12.35
52-wk high
Â¥5,040
52-wk low
Â¥3,500
EPS
Â¥332
Shares outstanding
46.72M
No. of employees
2K
Open
Â¥4,165
High
Â¥4,190
Low
Â¥4,095
Mkt. cap
190.59B
Avg. vol.
130.81K
Volume
100.80K
Dividend
2.93%
Quarterly dividend
Â¥30
Ex-dividend date
Mar 30, 2026
P/E ratio
12.35
52-wk high
Â¥5,040
52-wk low
Â¥3,500
EPS
Â¥332
Shares outstanding
46.72M
No. of employees
2K
News stories
From sources across the web
TipRanks
·
22 hours ago
Kissei Pharmaceutical Reports No Share Buybacks Yet Under 2026 Repurchase Program
Profile
Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include:
Difelikefalin
Fostamatinib
Linzagolix
Mitiglinide
Remogliflozin etabonate
Silodosin
Tranilast
In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China. Wikipedia
About Kissei Pharmaceutical Co Ltd
CEOMutsuo Kanzawa
Employees1.79K
FoundedAug 9, 1946
HeadquartersMatsumoto, Nagano, Japan
SectorPharmaceutical industry
Websitekissei.co.jp
AI content may include mistakes. Learn more